Release Date: May 30, 2025
Expiration Date: May 30, 2026
Activity Overview
Congenital adrenal hyperplasia (CAH) is a group of rare autosomal recessive disorders that arise from genetic mutation affecting enzymes involved in cortisol synthesis. Depending on the severity of mutations and the loss of functionality of 21-hydroxylase, CAH can take 2 primary forms: a severe-classical (presenting as salt-wasting or simple virilizing forms), and a mild non-classical. It is important that health care professionals receive education regarding the clinical presentation of CAH and optimal approaches to diagnosis and treatment. This Cases and Conversation activity features expert faculty discussing relevant clinical data and guideline recommendations for diagnosis and management of CAH.
Target Audience
This educational initiative is directed toward all HCPs involved in the care of adult and pediatric patients with CAH, including but not limited to endocrinologists, pediatric endocrinologists, pediatricians, primary care providers, nurses, NPs, PAs, and RNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Implement diagnostic algorithms to identify patients with congenital adrenal hyperplasia
- Design individualized management plans using guideline recommendations for patients with congenital adrenal hyperplasia
- Assess clinical trial data for emerging agents for the treatment of congenital adrenal hyperplasia
Perrin C White, MD
Director, Pediatric Endocrinology
Professor of Pediatrics
UT Southwestern Medical Center
Dallas TX
Disclosures: Research Support: Neurocrine/Diurnal; Consultant: Neurocrine
Richard J. Auchus, MD, PhD
The James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine
Division of Metabolism, Endocrinology, and Diabetes
Departments of Internal Medicine and Pharmacology
University of Michigan
Chief, Endocrinology and Metabolism Section
Ann Arbor VA Medical Center
Ann Arbor, MI
Disclosures: Grant and Research Support: Adrenas Therapeutics, Corcept Therapeutics, Crinetics Pharmaceuticals, Mineralys Pharmaceuticals, Neurocrine Biosciences/Neurocrine UK, Recordati Rare Diseases, Spruce Biosciences; Consultant: Acerand Therapeutics, Aspect Biosystems, Astellas Pharmaceuticals, Blue Earth Diagnostics, Corcept Therapeutics, Crinetics Pharmaceuticals, H Lundbeck A/S, Neurocrine Biosciences/Neurocrine UK, Novo Nordisk, OMass Therapeutics, Quest Diagnostics, Recordati Rare Diseases, Sparrow Pharmaceuticals, Spruce Biosciences, Xeris Pharmaceuticals
Mimi Kim, MD, MSc
Associate Professor
Division of Pediatric Endocrinology
Children’s Hospital Los Angeles (CHLA)
Keck School of Medicine of University of Southern California
Los Angeles, CA
Disclosures: Grant and Research Support: Diurnal, Neurocrine Biosciences, Spruce Biosciences; Other: Steering Committee member for Spruce Biosciences; Advisor: Eton Pharmaceuticals
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here